---
schema_version: "secwatch.filing_event.v1"
accession: "0000929638-23-003305"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2023-11-29T23:59:59+00:00"
generated_at: "2026-06-07T20:33:53.913323+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# enGene appoints Ryan Daws as CFO and Head of Business Development; new CMO agreement with Richard Bryce

## Summary
- Ryan Daws appointed CFO and Head of Business Development, effective Nov 27, 2023; replaces Alexandre Grassin.
- Daws receives $440K base salary, 40% bonus, $143.5K signing bonus, and 232,000 stock options vesting over 4 years.
- CMO Richard Bryce enters employment agreement with $450K base, 40% bonus, eligibility for 153,000 stock options in 2024.
- Bryce's agreement provides severance: 12 months base salary plus benefits upon termination or change in control.
- enGene's lead program EG-70 in pivotal study for BCG-unresponsive NMIBC; interim data read-out expected mid-2024.

## SEC filing metadata
- accession: 0000929638-23-003305
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2023-11-29T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000092963823003305/0000929638-23-003305-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000092963823003305/a8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000929638-23-003305
- JSON: https://secwatch.observer/filing/0000929638-23-003305.json
- Plain text: https://secwatch.observer/filing/0000929638-23-003305.txt

## Key facts
- Executive change
  Ryan Daws was appointed as Chief Financial Officer and Head of Business Development at enGene Therapeutics Inc..
  - Action: appointed
  - Role: Chief Financial Officer and Head of Business Development
  source text: On November 27, 2023, Ryan Daws became Chief Financial Officer (“CFO”) and Head of Business Development of enGene Holdings Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000092963823003305/0000929638-23-003305-index.htm
- Executive change
  Alexandre Grassin departed as principal financial officer and principal accounting officer at enGene Therapeutics Inc..
  - Action: replaced
  - Role: principal financial officer and principal accounting officer
  source text: Mr. Daws replaced Alexandre Grassin as the Company’s principal financial officer and principal accounting officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000092963823003305/0000929638-23-003305-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.